CA2897581A1 - Method for treating cancer based on mutation status of k-ras - Google Patents
Method for treating cancer based on mutation status of k-ras Download PDFInfo
- Publication number
- CA2897581A1 CA2897581A1 CA2897581A CA2897581A CA2897581A1 CA 2897581 A1 CA2897581 A1 CA 2897581A1 CA 2897581 A CA2897581 A CA 2897581A CA 2897581 A CA2897581 A CA 2897581A CA 2897581 A1 CA2897581 A1 CA 2897581A1
- Authority
- CA
- Canada
- Prior art keywords
- individual
- cancer
- ras
- paclitaxel
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000035772 mutation Effects 0.000 title claims abstract description 413
- 238000000034 method Methods 0.000 title claims abstract description 289
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 264
- 201000011510 cancer Diseases 0.000 title claims abstract description 183
- 101710113436 GTPase KRas Proteins 0.000 claims abstract description 518
- 239000000203 mixture Substances 0.000 claims abstract description 319
- 239000002105 nanoparticle Substances 0.000 claims abstract description 266
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 259
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 256
- 239000003814 drug Substances 0.000 claims abstract description 248
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 225
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 193
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 190
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 189
- 102000009027 Albumins Human genes 0.000 claims abstract description 172
- 108010088751 Albumins Proteins 0.000 claims abstract description 172
- 229940123237 Taxane Drugs 0.000 claims description 217
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 215
- 238000011282 treatment Methods 0.000 claims description 182
- 102200006539 rs121913529 Human genes 0.000 claims description 91
- 102200006532 rs112445441 Human genes 0.000 claims description 89
- 102200006531 rs121913529 Human genes 0.000 claims description 89
- 102200006537 rs121913529 Human genes 0.000 claims description 84
- 102200006538 rs121913530 Human genes 0.000 claims description 84
- 102200006520 rs121913240 Human genes 0.000 claims description 80
- 102200007373 rs17851045 Human genes 0.000 claims description 75
- 102200006525 rs121913240 Human genes 0.000 claims description 71
- 102200006648 rs28933406 Human genes 0.000 claims description 71
- 102200006657 rs104894228 Human genes 0.000 claims description 62
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 41
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 41
- 102220014333 rs112445441 Human genes 0.000 claims description 41
- 102200006533 rs121913535 Human genes 0.000 claims description 41
- 102220197780 rs121434596 Human genes 0.000 claims description 40
- 241000282414 Homo sapiens Species 0.000 claims description 33
- 102200006541 rs121913530 Human genes 0.000 claims description 30
- 102220197834 rs121913535 Human genes 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 102220530637 Putative apolipoprotein(a)-like protein 2_G12F_mutation Human genes 0.000 claims description 20
- 102200006562 rs104894231 Human genes 0.000 claims description 20
- 102220197831 rs121913527 Human genes 0.000 claims description 20
- 102200006564 rs121917759 Human genes 0.000 claims description 20
- 102220334606 rs1348427922 Human genes 0.000 claims description 20
- 102200007376 rs770248150 Human genes 0.000 claims description 20
- 102220640055 Alpha-mannosidase 2_G12L_mutation Human genes 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 102220293980 rs143960528 Human genes 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 102200006540 rs121913530 Human genes 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 163
- 201000002528 pancreatic cancer Diseases 0.000 description 158
- 208000008443 pancreatic carcinoma Diseases 0.000 description 157
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 156
- 150000001413 amino acids Chemical group 0.000 description 106
- 102220100997 rs878854511 Human genes 0.000 description 86
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 64
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 47
- 201000010099 disease Diseases 0.000 description 46
- 201000001441 melanoma Diseases 0.000 description 42
- 239000000523 sample Substances 0.000 description 37
- 238000002560 therapeutic procedure Methods 0.000 description 35
- 230000004044 response Effects 0.000 description 29
- 230000003442 weekly effect Effects 0.000 description 28
- 230000004083 survival effect Effects 0.000 description 25
- 210000001519 tissue Anatomy 0.000 description 25
- 206010006187 Breast cancer Diseases 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 208000026310 Breast neoplasm Diseases 0.000 description 22
- 206010061289 metastatic neoplasm Diseases 0.000 description 22
- 206010035226 Plasma cell myeloma Diseases 0.000 description 21
- 206010060862 Prostate cancer Diseases 0.000 description 21
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 21
- 229960000397 bevacizumab Drugs 0.000 description 21
- 230000001394 metastastic effect Effects 0.000 description 21
- 229940079593 drug Drugs 0.000 description 20
- 206010061535 Ovarian neoplasm Diseases 0.000 description 19
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 18
- 208000006265 Renal cell carcinoma Diseases 0.000 description 18
- 210000000496 pancreas Anatomy 0.000 description 18
- 206010009944 Colon cancer Diseases 0.000 description 17
- 206010027476 Metastases Diseases 0.000 description 17
- 208000034578 Multiple myelomas Diseases 0.000 description 17
- 206010033128 Ovarian cancer Diseases 0.000 description 17
- 201000005202 lung cancer Diseases 0.000 description 17
- 208000020816 lung neoplasm Diseases 0.000 description 17
- 230000009401 metastasis Effects 0.000 description 17
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 16
- 238000001990 intravenous administration Methods 0.000 description 16
- 230000003902 lesion Effects 0.000 description 16
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 15
- 208000009956 adenocarcinoma Diseases 0.000 description 15
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 15
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 14
- -1 GEMZARC Chemical compound 0.000 description 14
- 150000007523 nucleic acids Chemical class 0.000 description 14
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 13
- 101710100111 SPARC Proteins 0.000 description 13
- 102100037599 SPARC Human genes 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 229960002949 fluorouracil Drugs 0.000 description 13
- 208000021039 metastatic melanoma Diseases 0.000 description 13
- 208000024891 symptom Diseases 0.000 description 13
- 238000002648 combination therapy Methods 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 108020004707 nucleic acids Proteins 0.000 description 12
- 201000009030 Carcinoma Diseases 0.000 description 11
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 229960004562 carboplatin Drugs 0.000 description 11
- 229960004768 irinotecan Drugs 0.000 description 11
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 11
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 10
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 10
- 229960004117 capecitabine Drugs 0.000 description 10
- 229960001756 oxaliplatin Drugs 0.000 description 10
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 10
- 230000036961 partial effect Effects 0.000 description 10
- 206010003571 Astrocytoma Diseases 0.000 description 9
- 206010055113 Breast cancer metastatic Diseases 0.000 description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 102220215075 rs1060500691 Human genes 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 206010025323 Lymphomas Diseases 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 208000005017 glioblastoma Diseases 0.000 description 8
- 208000037819 metastatic cancer Diseases 0.000 description 8
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 206010018338 Glioma Diseases 0.000 description 7
- 238000010240 RT-PCR analysis Methods 0.000 description 7
- 206010041067 Small cell lung cancer Diseases 0.000 description 7
- 206010043276 Teratoma Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 231100000682 maximum tolerated dose Toxicity 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 206010061818 Disease progression Diseases 0.000 description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 6
- 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 6
- 206010038389 Renal cancer Diseases 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 230000000683 nonmetastatic effect Effects 0.000 description 6
- 239000008389 polyethoxylated castor oil Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108700042226 ras Genes Proteins 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- 206010014967 Ependymoma Diseases 0.000 description 5
- 208000032612 Glial tumor Diseases 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 208000007452 Plasmacytoma Diseases 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000008366 buffered solution Substances 0.000 description 5
- 208000002458 carcinoid tumor Diseases 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 201000010982 kidney cancer Diseases 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 208000019420 lymphoid neoplasm Diseases 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 238000011277 treatment modality Methods 0.000 description 5
- KKZRPIKZBFQAKR-YPWTWYSKSA-N 4-amino-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;n-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1.C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 KKZRPIKZBFQAKR-YPWTWYSKSA-N 0.000 description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 4
- 208000012526 B-cell neoplasm Diseases 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 4
- 208000000172 Medulloblastoma Diseases 0.000 description 4
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 4
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 239000012736 aqueous medium Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 208000030381 cutaneous melanoma Diseases 0.000 description 4
- 230000001066 destructive effect Effects 0.000 description 4
- 229960003668 docetaxel Drugs 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000009093 first-line therapy Methods 0.000 description 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical group C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 4
- 235000008191 folinic acid Nutrition 0.000 description 4
- 239000011672 folinic acid Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000001794 hormone therapy Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 229960001691 leucovorin Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000002493 microarray Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 4
- 208000037821 progressive disease Diseases 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000000306 recurrent effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 208000005893 serous cystadenoma Diseases 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 3
- 108700020462 BRCA2 Proteins 0.000 description 3
- 206010005949 Bone cancer Diseases 0.000 description 3
- 208000018084 Bone neoplasm Diseases 0.000 description 3
- 101150008921 Brca2 gene Proteins 0.000 description 3
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 3
- 208000009798 Craniopharyngioma Diseases 0.000 description 3
- 208000001154 Dermoid Cyst Diseases 0.000 description 3
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000000164 Familial pancreatic carcinoma Diseases 0.000 description 3
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 229940028652 abraxane Drugs 0.000 description 3
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000024519 eye neoplasm Diseases 0.000 description 3
- 201000003444 follicular lymphoma Diseases 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 201000002222 hemangioblastoma Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000003731 mucosal melanoma Diseases 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 201000000032 nodular malignant melanoma Diseases 0.000 description 3
- 201000008106 ocular cancer Diseases 0.000 description 3
- 201000002575 ocular melanoma Diseases 0.000 description 3
- 208000021284 ovarian germ cell tumor Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 102200006593 rs727503093 Human genes 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 201000003708 skin melanoma Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 2
- 206010060971 Astrocytoma malignant Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 206010006143 Brain stem glioma Diseases 0.000 description 2
- 206010065305 Cancer in remission Diseases 0.000 description 2
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 201000005171 Cystadenoma Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 208000021994 Diffuse astrocytoma Diseases 0.000 description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010018404 Glucagonoma Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 208000028572 Hereditary chronic pancreatitis Diseases 0.000 description 2
- 206010056976 Hereditary pancreatitis Diseases 0.000 description 2
- 206010067943 Hereditary papillary renal carcinoma Diseases 0.000 description 2
- 208000027927 Hereditary papillary renal cell carcinoma Diseases 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- 206010070999 Intraductal papillary mucinous neoplasm Diseases 0.000 description 2
- 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
- 206010023825 Laryngeal cancer Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 206010024218 Lentigo maligna Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010051676 Metastases to peritoneum Diseases 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010029488 Nodular melanoma Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 2
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 2
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 2
- 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000006336 acinar cell carcinoma Diseases 0.000 description 2
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 201000009036 biliary tract cancer Diseases 0.000 description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 102220364120 c.32C>T Human genes 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 201000007335 cerebellar astrocytoma Diseases 0.000 description 2
- 208000030239 cerebral astrocytoma Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000024207 chronic leukemia Diseases 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 description 2
- 208000012106 cystic neoplasm Diseases 0.000 description 2
- 238000009110 definitive therapy Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 208000027858 endometrioid tumor Diseases 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 201000004753 familial renal oncocytoma Diseases 0.000 description 2
- 201000005306 familial renal papillary carcinoma Diseases 0.000 description 2
- 201000010972 female reproductive endometrioid cancer Diseases 0.000 description 2
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000005376 hepatoid adenocarcinoma Diseases 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 208000024635 hereditary kidney oncocytoma Diseases 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 2
- 208000037393 large granular lymphocyte leukemia Diseases 0.000 description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 description 2
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 2
- 208000030883 malignant astrocytoma Diseases 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 2
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 2
- 208000004707 mucinous cystadenoma Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 208000002820 pancreatoblastoma Diseases 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 208000010918 peritoneal neoplasm Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000009101 premedication Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 229910052704 radon Inorganic materials 0.000 description 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 102220117341 rs11554290 Human genes 0.000 description 2
- 102220197778 rs121913254 Human genes 0.000 description 2
- 102200006663 rs121917757 Human genes 0.000 description 2
- 102200042492 rs149991239 Human genes 0.000 description 2
- 102220091421 rs876657848 Human genes 0.000 description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 2
- 230000037432 silent mutation Effects 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 201000005211 struma ovarii Diseases 0.000 description 2
- 208000030457 superficial spreading melanoma Diseases 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 210000000239 visual pathway Anatomy 0.000 description 2
- 230000004400 visual pathway Effects 0.000 description 2
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102220496225 Aryl hydrocarbon receptor nuclear translocator-like protein 1_M67L_mutation Human genes 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 102220554407 Choriogonadotropin subunit beta 3_T35I_mutation Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010072449 Desmoplastic melanoma Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 208000005431 Endometrioid Carcinoma Diseases 0.000 description 1
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000012468 Ewing sarcoma/peripheral primitive neuroectodermal tumor Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 102220481335 G-protein coupled receptor family C group 5 member D_A18D_mutation Human genes 0.000 description 1
- 102100030708 GTPase KRas Human genes 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000017605 Hodgkin disease nodular sclerosis Diseases 0.000 description 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 1
- 101100478240 Homo sapiens SPARC gene Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 206010069755 K-ras gene mutation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 1
- 101150105104 Kras gene Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 description 1
- 206010025342 Lymphoplasmacytoid lymphoma/immunocytoma Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 206010073059 Malignant neoplasm of unknown primary site Diseases 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000006395 Meigs Syndrome Diseases 0.000 description 1
- 206010027139 Meigs' syndrome Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000006098 Neonatal Hyperbilirubinemia Diseases 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 206010033268 Ovarian low malignant potential tumour Diseases 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150118944 PRSS1 gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010048734 Phakomatosis Diseases 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 206010050487 Pinealoblastoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000032758 Precursor T-lymphoblastic lymphoma/leukaemia Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037127 Pseudolymphoma Diseases 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- 206010042658 Sweat gland tumour Diseases 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 206010042970 T-cell chronic lymphocytic leukaemia Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100033254 Tumor suppressor ARF Human genes 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 208000019297 Well-differentiated fetal adenocarcinoma of the lung Diseases 0.000 description 1
- ZSTCHQOKNUXHLZ-PIRIXANTSA-L [(1r,2r)-2-azanidylcyclohexyl]azanide;oxalate;pentyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate;platinum(4+) Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@@H]1CCCC[C@H]1[NH-].C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 ZSTCHQOKNUXHLZ-PIRIXANTSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- HSUDWURBWSUCOB-JPHWUADUSA-N ac1l907a Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](OC(=O)OCC(O)CO)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 HSUDWURBWSUCOB-JPHWUADUSA-N 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 208000018234 adnexal spiradenoma/cylindroma of a sweat gland Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 208000016894 basaloid carcinoma Diseases 0.000 description 1
- 201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 1
- 201000007180 bile duct carcinoma Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical class ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 208000012172 borderline epithelial tumor of ovary Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 102200115869 c.186G>T Human genes 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 229940001981 carac Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011342 chemoimmunotherapy Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical class [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 201000010276 collecting duct carcinoma Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 201000004434 cystic teratoma Diseases 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002146 exchange transfusion Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000021173 high grade B-cell lymphoma Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 208000015266 indolent plasma cell myeloma Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000007785 kidney angiomyolipoma Diseases 0.000 description 1
- 210000000244 kidney pelvis Anatomy 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 201000005274 large cell carcinoma with rhabdoid phenotype Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000011299 local ablative therapy Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000016992 lung adenocarcinoma in situ Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 201000000966 lung oat cell carcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000037829 lymphangioendotheliosarcoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000000271 mature teratoma Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 208000029691 metastatic malignant neoplasm in the lymph nodes Diseases 0.000 description 1
- 208000037970 metastatic squamous neck cancer Diseases 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 241000514897 mixed subtypes Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
- 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 208000018795 nasal cavity and paranasal sinus carcinoma Diseases 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 208000016450 non-cutaneous melanoma Diseases 0.000 description 1
- 208000015270 non-secretory plasma cell myeloma Diseases 0.000 description 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000009116 palliative therapy Methods 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 201000002530 pancreatic endocrine carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 201000003113 pineoblastoma Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 102220039480 rs104886028 Human genes 0.000 description 1
- 102200006535 rs104894361 Human genes 0.000 description 1
- 102200006534 rs104894365 Human genes 0.000 description 1
- 102220224223 rs1060499970 Human genes 0.000 description 1
- 102220226389 rs1064794129 Human genes 0.000 description 1
- 102220228930 rs1064795404 Human genes 0.000 description 1
- 102220243326 rs1183892581 Human genes 0.000 description 1
- 102220084967 rs121913538 Human genes 0.000 description 1
- 102200006667 rs121917758 Human genes 0.000 description 1
- 102220257835 rs1236604706 Human genes 0.000 description 1
- 102220284259 rs1379395211 Human genes 0.000 description 1
- 102220040905 rs150548839 Human genes 0.000 description 1
- 102220309985 rs1554139870 Human genes 0.000 description 1
- 102220334607 rs1554885139 Human genes 0.000 description 1
- 102200006522 rs193929331 Human genes 0.000 description 1
- 102200097053 rs199473666 Human genes 0.000 description 1
- 102200124922 rs267606920 Human genes 0.000 description 1
- 102220005331 rs281865555 Human genes 0.000 description 1
- 102200082941 rs33915112 Human genes 0.000 description 1
- 102220286835 rs560518923 Human genes 0.000 description 1
- 102220316666 rs587780536 Human genes 0.000 description 1
- 102220056978 rs730880472 Human genes 0.000 description 1
- 102220058925 rs750058876 Human genes 0.000 description 1
- 102220086655 rs864622484 Human genes 0.000 description 1
- 102220088287 rs869025573 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 238000009094 second-line therapy Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000037992 stage IV cutaneous melanoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000002620 vena cava superior Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361848793P | 2013-01-11 | 2013-01-11 | |
| US61/848,793 | 2013-01-11 | ||
| US201361752417P | 2013-01-14 | 2013-01-14 | |
| US61/752,417 | 2013-01-14 | ||
| US13/794,712 | 2013-03-11 | ||
| US13/794,712 US20140199405A1 (en) | 2013-01-11 | 2013-03-11 | Method for treating cancer based on mutation status of k-ras |
| PCT/US2014/011097 WO2014110408A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2897581A1 true CA2897581A1 (en) | 2014-07-17 |
Family
ID=51165319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2897581A Abandoned CA2897581A1 (en) | 2013-01-11 | 2014-01-10 | Method for treating cancer based on mutation status of k-ras |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20140199405A1 (Direct) |
| EP (1) | EP2943184A4 (Direct) |
| JP (1) | JP2016506908A (Direct) |
| KR (1) | KR20150103746A (Direct) |
| AU (1) | AU2014205254A1 (Direct) |
| BR (1) | BR112015016466A2 (Direct) |
| CA (1) | CA2897581A1 (Direct) |
| HK (1) | HK1217292A1 (Direct) |
| IL (1) | IL239740A0 (Direct) |
| MX (1) | MX2015008889A (Direct) |
| WO (1) | WO2014110408A1 (Direct) |
| ZA (1) | ZA201504878B (Direct) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| MX383644B (es) | 2005-02-18 | 2025-03-14 | Abraxis Bioscience Llc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
| BRPI0615265A8 (pt) | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
| ES2548690T3 (es) | 2006-08-11 | 2015-10-20 | Johns Hopkins University | Secuencias consenso de codificación de cánceres colorrectales humanos |
| EP2117520B1 (en) | 2006-12-14 | 2018-08-29 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| DK2155188T3 (da) * | 2007-06-01 | 2013-11-04 | Abraxis Bioscience Llc | Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft |
| EP3626233A1 (en) | 2009-04-15 | 2020-03-25 | Abraxis BioScience, LLC | Prion-free nanoparticle compositions and methods |
| ES2580135T3 (es) | 2010-03-26 | 2016-08-19 | Abraxis Bioscience, Llc | Métodos de tratamiento de carcinoma hepatocelular |
| KR20180050426A (ko) | 2010-03-29 | 2018-05-14 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| CA2801645A1 (en) | 2010-06-04 | 2011-12-08 | Abraxis Bioscience, Llc | Use of nanoparticules comprising a taxane and an albumin in the treatment of pancreatic cancer |
| CN103648521A (zh) | 2011-04-28 | 2014-03-19 | 阿布拉科斯生物科学有限公司 | 纳米颗粒组合物的血管内递送及其应用 |
| KR20140107417A (ko) | 2011-12-14 | 2014-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| WO2014159171A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| SG11201507234UA (en) | 2013-03-14 | 2015-10-29 | Abraxis Bioscience Llc | Methods of treating bladder cancer |
| JP6781403B2 (ja) | 2013-12-09 | 2020-11-04 | タルゴバックス エーエスエー | ペプチド混合物 |
| EP3140320B1 (en) | 2014-05-06 | 2018-12-26 | Targovax Asa | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| HUE070408T2 (hu) | 2015-06-29 | 2025-06-28 | Abraxis Bioscience Llc | Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra |
| EP3522887A4 (en) * | 2016-10-07 | 2020-06-10 | Abraxis BioScience, LLC | METHODS OF TREATING BILARIAN CANCER |
| EP3444272A1 (en) * | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Treatment of ck8 positive cancers in relation with k-ras gene status |
| AU2019239953B2 (en) | 2018-03-20 | 2025-01-02 | Abraxis Bioscience, Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| KR20220106758A (ko) | 2019-10-28 | 2022-07-29 | 아브락시스 바이오사이언스, 엘엘씨 | 알부민 및 라파마이신의 제약 조성물 |
| CN115867669A (zh) * | 2020-05-08 | 2023-03-28 | 凯帝夫肿瘤科技有限公司 | 监测kras突变的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383644B (es) * | 2005-02-18 | 2025-03-14 | Abraxis Bioscience Llc | Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion. |
| US20090202989A1 (en) * | 2005-06-28 | 2009-08-13 | Hillan Kenneth J | Egfr and kras mutations |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| DK2465950T3 (en) * | 2007-03-13 | 2017-10-09 | Amgen Inc | K-RAS MUTATIONS AND ANTI-EGFR ANTIBODY TREATMENT |
| WO2011116181A1 (en) * | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| DK2470173T3 (en) * | 2009-08-25 | 2016-06-06 | Abraxis Bioscience Llc | Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors |
| KR101894689B1 (ko) * | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| US9469876B2 (en) * | 2010-04-06 | 2016-10-18 | Caris Life Sciences Switzerland Holdings Gmbh | Circulating biomarkers for metastatic prostate cancer |
| AU2011255438A1 (en) * | 2010-05-20 | 2013-01-10 | Synta Pharmaceuticals Corp. | Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds |
| US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| EP3444363B1 (en) * | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2013134786A2 (en) * | 2012-03-09 | 2013-09-12 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Biomarker compositions and methods |
| AU2013201584A1 (en) * | 2012-03-12 | 2013-09-26 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody |
-
2013
- 2013-03-11 US US13/794,712 patent/US20140199405A1/en not_active Abandoned
-
2014
- 2014-01-10 KR KR1020157021321A patent/KR20150103746A/ko not_active Withdrawn
- 2014-01-10 BR BR112015016466A patent/BR112015016466A2/pt not_active Application Discontinuation
- 2014-01-10 WO PCT/US2014/011097 patent/WO2014110408A1/en not_active Ceased
- 2014-01-10 HK HK16105270.2A patent/HK1217292A1/zh unknown
- 2014-01-10 MX MX2015008889A patent/MX2015008889A/es unknown
- 2014-01-10 EP EP14738060.4A patent/EP2943184A4/en not_active Withdrawn
- 2014-01-10 JP JP2015552819A patent/JP2016506908A/ja active Pending
- 2014-01-10 AU AU2014205254A patent/AU2014205254A1/en not_active Abandoned
- 2014-01-10 CA CA2897581A patent/CA2897581A1/en not_active Abandoned
-
2015
- 2015-07-01 IL IL239740A patent/IL239740A0/en unknown
- 2015-07-07 ZA ZA2015/04878A patent/ZA201504878B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014110408A1 (en) | 2014-07-17 |
| JP2016506908A (ja) | 2016-03-07 |
| IL239740A0 (en) | 2015-08-31 |
| EP2943184A4 (en) | 2016-07-20 |
| BR112015016466A2 (pt) | 2017-07-11 |
| MX2015008889A (es) | 2015-11-13 |
| US20140199405A1 (en) | 2014-07-17 |
| EP2943184A1 (en) | 2015-11-18 |
| AU2014205254A1 (en) | 2015-07-23 |
| ZA201504878B (en) | 2016-10-26 |
| HK1217292A1 (zh) | 2017-01-06 |
| KR20150103746A (ko) | 2015-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2897581A1 (en) | Method for treating cancer based on mutation status of k-ras | |
| US10328031B2 (en) | Methods of treating pancreatic cancer | |
| US20140199404A1 (en) | Method for treating cancer based on level of a nucleoside transporter | |
| US9370494B2 (en) | Methods for treating hepatocellular carcinoma | |
| US20200246275A1 (en) | Combination therapy comprising nanoparticles of a taxane and albumin with abt-263 in methods for treating cancer | |
| US20180064679A1 (en) | Method for treating cancer based on level of glucocorticoid receptor | |
| US20200040398A1 (en) | Methods of treating cancer | |
| KR20190130050A (ko) | 췌장암의 치료 방법 | |
| US20160015681A1 (en) | Methods of treating lung cancer | |
| HK40009403A (en) | Methods of treating pancreatic cancer | |
| AU2011235344B2 (en) | Methods of treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20200110 |